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Background. Secretions accumulate in endotracheal tubes’ (ETT) lumens upon their placement in patients. The secretions impact
airway resistance and pressure. Secretions potentiate prolonged mechanical ventilation and ventilator-associated pneumonia. Our
primary objective in this study was to evaluate an ETT-clearing device (ETT-CD) in its ability to remove secretions from ex vivo
ETT lumens. Methods. Forty ETTs, obtained from intensive care patients at extubation, were individually placed into a ventilator
ﬁeld performance testing simulator at 37°C. The pressure drop through the ETTs was measured at a ﬂow rate of 60 L/min before
and after cleaning with the ETT-CD and compared with unused, similarly sized controls tubes. The ETT-CD was inserted into an
ETT until the tip reached Murphy’s eye (hole in the side) of the ETT. The wiper, set back from the tip, was expanded by ETT-CD
handle activation. As the ETT-CD was removed, the distal wiper extracted secretions from the ETT lumen. Results. Forty ETTs
were tested with nonparametric Wilcoxon signed-rank tests. Before being cleared with the ETT-CD, the median pressure drop in
the extubated 7.5 mm ETTs was 17.8 cm H2O; after ETT-CD use, it was 12.3. The cleared ETTs were signiﬁcantly improved over
the ETTs before being cleared (p < 0.001); however, there remained a signiﬁcant diﬀerence between the cleared ETTs and the
control tubes (p � 0.005), indicating the clearing was not to the level of an unused ETT. Similar results were determined for the
8.0 mm ETTs. Conclusions. For the 7.5 mm and the 8.0 mm EETs, the ETT-CD improved eﬀective patency of the ETTs over the
uncleared ETTs, independent of occlusion location, tube size, or length of tube. However, there remained a signiﬁcant diﬀerence
between the cleared tubes and controls.

1. Introduction
The physical and economic burdens of ventilator-associated
pneumonia (VAP) have been well documented and recognized as major consequences of mechanical ventilation
(MV). VAP has signiﬁcant morbidity, mortality, and cost
[1]. The ﬁnancial burden and demand upon resources are
between approximately $40,000 and $90,000 per mechanically ventilated patient [2]. Patients’ quality of life is impacted by VAP discomfort and the burden of additional
hospital stay. Depending upon how VAP is deﬁned, it occurs
in approximately 10% [3] of adults aged 65 years and above.

The VAP incidence has been relatively stable and high [3].
Thus, there is a critical need to develop new preventative
strategies against the development of VAP in mechanically
ventilated patients.
Initially, preventative strategies for VAP were focused on
the positive pressure ventilator and reducing microbial
contamination with heating elements in the airway tubing
[4]. Antimicrobial therapy was (and is) used routinely in the
management of VAP in critically ill patients. However, due
to the emergence of multidrug-resistant or extremely drugresistant pathogens [5], alternatives to antimicrobial therapies are needed. Therefore, the focus began to change to
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limiting bioﬁlm development and/or reducing bioﬁlm load
and secretions in the lumens of endotracheal tubes (ETT)
through the use of noninvasive management teams to
monitor patients on MV with daily oral infection control [6].
The concept is valid, although healthcare personnel compliance with such protocols is problematic [7].
The secretions, including oral microﬂora, create a bioﬁlm which has the potential to accumulate above the ETT
cuﬀ. These secretions then enter the ETT proper and adhere
to the ETT lumen causing a constriction [6, 8]. Constriction
of the lumen results in airway resistance and pressure drop
in ETT during MV.
An ETT lumen during MV is a consistent surface for
microbial colonization since the ends of an ETT are under
constant parallel lines of force, while the central curve of the
tube experiences a vortexing action [9]. As the bioﬁlm
develops and secretions adhere, the lumen of an ETT occludes and narrows. To clear secretions from the ETT lumen,
closed-system suctioning is periodically employed [10].
However, it was reported that the incomplete removal of
secretions during suctioning was found to be a factor in the
narrowing of an ETT’s lumen [11, 12].
Secretions and bioﬁlms accumulate quickly and unpredictably [13, 14]. When they detach from the luminal
ETT, they can project deep within the lungs (up to 45 cm
from the end of the ETT) [15]. It should be noted that, in
addition to an ETT having secretions that can enter the
lungs, oral bacteria may migrate quickly from the mouth
during intubation and contribute to VAP pathogenesis [16].
ETT lumenal occlusion with bioﬁlm and secretion,
which is unpredictable of MV time [17], may result in VAP
or other infections in the lungs. This should be considered
when weaning is diﬃcult, even for patients ventilated for less
than one day [18]. ETT obstruction may mislead clinicians
on the readiness of patients for extubation and subsequently
lead to unnecessary prolongation of intubation and MV
[19, 20].
In the designed study, we hypothesized that using a novel
federally registered medical device to clear bioﬁlm secretions
from the ETT lumens would return the ETT to luminal
patency. To test this hypothesis, we designed a study aimed
at measuring the impact of an ETT clearing device (ETTCD) (EndOclear Restore device, previously named
EndOclear endotracheal tube clearing device) within
controlled ex vivo conditions. To demonstrate an ex vivo
model, we designed a multistation ventilator ﬁeld performance testing simulator for data acquisition.

medical histories, dates, times of intubation and extubation,
length of ETT intubation (days), and clinical and ventilator
information were recorded in a database.
2.1. Ex Vivo Measurements. The setting, testing design, and
calibration method of the pressure drop test apparatus were
published previously [13]. The simulation device was
modiﬁed with an engineered heat-regulated tracheal feature
with a temperature sensor probe to maintain the ex vivo
ETTs at 37°C (body temperature) while conducting the
research. Additionally, the new design included the positioning of the engineered heated head at a 30° anatomically
correct head position following Institute for Healthcare
Improvement guidelines that would be in place during
patient care. The modiﬁcated design is referred to as the
multistation ventilator ﬁeld performance testing simulator
(Supplemental Figure 1). The setup closely duplicated the in
vivo anatomy and temperature of a human who has an ETT
in place allowing for the measure of the true impact of airway
resistance of the ex vivo ETTs.

2. Materials and Methods

2.2. Control Tubes. Standard ETTs (Hi-Lo; Mallinckrodt,
Inc; St. Louis, MO) sizes at 6.5, 7.0, 7.5, and 8.0 mm internal
diameter were evaluated and used as baseline controls. Each
control ETT was placed and secured, by cuﬀ inﬂation, into
the multistation ventilator ﬁeld performance testing simulator set at 37°C. A high-eﬃciency particulate arresting
(HEPA) air breathing ﬁlter (Iso-Gard® HEPA Light 28022;
Hudson RCI; Temecula, CA) was attached to the proximal
end of each control tube for consistency when comparing
the control tube with a patient’s ex vivo tube, as the ex vivo
tubes needed the HEPA ﬁlter to minimize potential exposure
to biohazard material.
Pressure drop was measured by opening an air ﬂow
control valve of compressed air set to a pressure of 2109 cm
H2O (30 pounds per square inch, psi) at a controlled rate
from 0 to 100 liters per minute (L/min) over 30 seconds.
Data acquisition of the mass ﬂow rate through the mass ﬂow
meter and pressure transducer (PTS-2000; Mallinckrodt,
Inc; St. Louis, MO), using specialized software (Puritan
Bennett Breathlab PTS Respiratory Products Test Software, V. 2.0 Rev. B; Mallinckrodt, Inc), was set to 72
measurements per second. The collected pressure drop data
were repeated three times, averaged, logged, analyzed, and
evaluated at 30, 60, and 90 L/min for reliability (Supplemental Figure 2). We focused on 60 L/min as this ﬂow rate
achieved optimal gas exchange in most critically ill, intubated adult patients [21, 22].

This study was conducted at West Virginia University
Hospital in association with the Department of Pathology
and was approved by the West Virginia University Institutional Review Board (IRB H-23234). Forty ETTs were
randomly obtained from adult patients at the time of
extubation from a combined Medical/Surgical Intensive
Care Units (MICU/SICU). All ETTs of adult patients (age
>18 years old) were eligible for collection, unless the patient
was diagnosed with tuberculosis and/or HIV. Patient

2.3. Sample Tubes. Extubated ETTs were collected and immediately placed in a biohazard bag with sterile gauze wetted
with 4 ml of sterile saline and sealed to avoid dehumidiﬁcation during the transportation to the laboratory.
Using the same methods as for the control tubes, the ex vivo
ETTs were connected to the multistation ventilator ﬁeld
performance testing simulator set at 37°C. The initial set of
pressure drop data (cm H2O), referred to as the before
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clearing data (pre), was obtained using the same method as
for the control tubes.
Then, each ex vivo ETT was cleared with the ETT clearing
device (ETT-CD) (EndOclear Restore device, endOclear ,
Inc., Petoskey MI), a federally registered (FR Doc. 2011–21685
Filed 8-23-11; 8:45 am) medical device. The ETT-CD was
designed with a ﬂexible central tube and a smooth discshaped wiper at its distal end (Supplemental Figure 3). The
ETT-CD was inserted into the ETT until the tip reached
Murphy’s eye (hole in the side) of the ETT. The disc-shaped
wiper, set back from the tip, was expanded by activating the
handle of the device (Supplemental Figure 4). Once deployed,
the wiper is ﬁrmly engaged with the inside walls of the ETT, in
its activation mode. The ETT-CD was then removed,
extracting bioﬁlm secretions with the wiper. The insertion,
positioning, and clearing of the ETT (distal end ﬁrst) required
approximately 8 seconds. A second set of pressure drop data
(cm H2O), referred to as the cleared data (post), were obtained
using the same method as for the control and preclearing
ETTs data collection procedures.
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2.4. Statistical Analysis. Data were organized by tube size.
Pressure drops were tabulated and compared with the sizematched control tubes [13]. JMP v. 9.0.0 and SPSS version 20
(SAS Institute Inc; Cary, NC) software were used to perform
data analyses. Nonparametric statistical tests were used due
to sample size. Related-samples Wilcoxon signed-rank tests
were used to compare the ETTs before being cleared and
after being cleared. One sample (vs. median control pressure
drop) Wilcoxon signed-rank tests was used to compare the
control tubes with the ex vivo tubes before clearing and after
clearing. Signiﬁcance was accepted at an alpha of <0.05.

3. Results
Studied ex vivo ETTs were from 23 male and 17 female
patients with a mean patient age of 53 years (SD ± 18). The
ETTs were from 15 patients diagnosed with pneumonia, 10
with a history of smoking, 12 with COPD, 22 who had fever,
and 30 who received antibiotic therapy. Eight ETTs were
reintubations and 31 ETTs were from patients who were on
MV over 48 hours. Respiratory failure was the most prevalent reason for intubation. The collected ETTs had been in
use for a mean of 2.6 days of intubation and were composed
of three sizes: 7.0; 7.5; and 8.0 mm (Table 1).
3.1. Before Clearing the Ex Vivo ETTs versus Control Tube
Results. There was a signiﬁcant diﬀerence between the ex
vivo ETTs’ before being cleared and the control tubes indicating obstruction in the ex vivo ETTs as compared with
the control tubes for sizes 7.5 mm and 8.0 mm (p < 0.001).
There was no signiﬁcant diﬀerence between the size 7.0 mm
ex vivo ETTs and the control tubes (p � 0.068).
3.2. Before Clearing the Ex Vivo ETTs versus the Cleared Ex
Vivo ETTs Results. The overall median pressure drop for the
ex vivo ETTs (n � 40) before clearing was 17.5 cm H2O

Table 1: Characteristics of the study population.
Variable
Age ± SD
Height (in.)
Weight (kg)
Hospital LOS (days)
ICU LOS (days)
Vent days
LOI (days) for ETTs obtained
History
Male patients
Female patients
Smokers
Patients on antibiotic therapy
Patients on ventilator >48 hours
Comorbidities
Reintubation
Pneumonia prior to intubation
Pneumonia following intubation
Total pneumonia
History of tracheostomy
COPD
Fever
Reason for intubation
Respiratory failure
Others (surgery, respiratory arrest, drug OD)

Mean (SD)
53.02 (17.89)
67.59 (4.73)
86.18 (31.13)
17.5 (12.42)
8.8 (6.90)
3.1 (2.49)
2.60 (2.32)
n (% of total)
23 (57.5%)
17 (42.5%)
10 (25.6%)
30 (81.08%)
31 (77.5%)
8 (20.0%)
9 (22.5%)
13 (32.5%)
15 (37.5%)
3 (7.5%)
12 (30%)
22 (59.46%)
21 (52.5%)
19 (47.5%)

(minimum � 10.2 cm H2O; maximum � 77.8 cm H2O). The
overall median pressure drop after clearing was 11.4 cm H2O
(minimum � 9.5 cm H2O; maximum � 16.8 cm H2O).
There was a signiﬁcant diﬀerence in the ex vivo ETT
lumens before being cleared and after being cleared for sizes
7.5 mm and 8.0 mm tubes (p < 0.001), indicating a diﬀerence
in pressure drop due to lumen obstruction being cleared
after the use of the ETT-CD. There was no signiﬁcant difference in the 7.0 mm tubes. The results are summarized in
Table 2.
3.3. Cleared Ex Vivo ETTs versus Control Tubes Results.
There was signiﬁcant diﬀerence in the cleared ex vivo ETT
lumens and the control tubes for the sizes 7.5 mm and
8.0 mm (p < 0.001), indicating a diﬀerence remained in
pressure drop between the cleared tubes and the control
tubes. There was no signiﬁcant diﬀerence in the 7.0 mm
tubes.
The majority of the cleared ET tubes were within 5–13%
of the pressure drop observed in control tubes. Utilization of
the ETT-CD resulted in a 22–145% decrease in pressure drop
in all ET tubes at 60 L/minute. The average percent increase
in pressure drop from control tubes for the remaining ﬂow
rates at sizes 7.0, 7.5, and 8.0 mm are displayed in Supplemental Figure 5.
Pressure drop data from ETTs before clearing were
compared to control tubes to assess functionality of a smaller
tube size at 60 L/min. 1 of 4 ETTs (7.0 mm), 11 of 17 ETTs
(7.5 mm), and 14 of 19 ETTs (8.0 mm) had a pressure drop
equivalent to 1 size smaller. ETT sizes 7.5 mm and 8.0 mm
presented greater pressure drops compared to controls of
smaller sizes. 7 of 17 ETTs (7.5 mm) and 12 of 19 ETTs
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Table 2: Pressure drop characteristics of tested and control endotracheal tubes at 60 L/minute.

Type of
endotracheal tube
All endotracheal
tubes
All controls
Extubated, not
cleared (pre)
Extubated, cleared
(post)
7.0 mm diameter
Control
Extubated, not
cleared (pre)
Extubated, cleared
(post)
7.5 mm diameter
Control
Extubated, not
cleared (pre)
Extubated, cleared
(post)
8.0 mm diameter
Control
Extubated, not
cleared (pre)
Extubated, cleared
(post)

Min.
pressure
drop

Max.
pressure
drop

n

Mean
pressure drop

Standard
deviation

3

10.8

0.27

40

21.8

13.30

10.2

77.8

5.27

40

11.8

0.29

9.5

16.8

−8.63

1

14.5

0.14

4

19.2

1.88

16.4

20.4

4.94

4

15.9

0.75

15.0

16.8

−3.69

1

11.8

0.01

17

24.1

9.12

12.0

46.0

4.33

17

12.5

0.86

11.4

14.3

−3.30

1

9.1

0.04

19

23.0

17.42

10.2

77.8

3.55

19

10.3

0.48

9.5

11.3

−10.76

t-test value vs.
control

t-test value vs
cleared tube

p
value

−8.63

<0.001

<0.001

4.80

<0.001

<0.001

n/a

p
value

n/a

n/a

−3.69

0.035

0.016

5.20

0.014

0.035

n/a

n/a

−3.30

0.004

<0.001

4.13

0.001

0.004

n/a

n/a

(8.0 mm) had a pressure drop equivalent to 2 sizes smaller.
Detailed percentage of ET tubes functioning at smaller sizes,
prior to clearing, is outlined in Supplemental Table 1.

4. Discussion
Forty extubated ETTs were randomly obtained from
mechanically ventilated adult patients from a combined
Medical/Surgical Intensive Care Units (MICU/SICU). The
ETTs were placed into a simulator’s anatomical trachea,
duplicating in vivo placement, thereby creating a more realistic experimental platform. The ETT-CD improved the
eﬀective patency of cleared ETTs versus ETTs before clearing
for the 7.5 mm and 8.0 mm (p < 0.001); however, compared
with control tubes, some secretion remained (p < 0.001). The
ETT-CD was eﬀective in this study in improving the
pressure change between the 7.5 mm and 8.0 mm ETTs
before being cleared and after being cleared through the
entire length of the tube, experiencing no issues in the
navigation of the curvature of the simulated anatomical
trachea while the head was in the 30° resting position.
Signiﬁcant obstruction to respiratory ﬂow begins within
hours following tracheal intubation as a result of bioﬁlm
occlusion within the ETTs’ lumen. Bioﬁlm occlusion in the
ETT lumen results from the accumulation of secretions and
from the colonization of fungal and bacterial organisms
[23, 24]. Researchers have shown that contaminated oropharyngeal secretions and/or gastric contents pool above
the inﬂated ETT cuﬀ in the subglottic space, causing

−10.76

<0.001

0.002

3.23

0.004

<0.001

n/a

microaspiration, tracheobronchial colonization, and VAP
incidence [25, 26]. Leakage of subglottic secretions around
the cuﬀ (between ETT and tracheal mucosa) reach the distal
airways within hours following endotracheal intubation [13,
26–30]. Once in the distal airways, contaminated secretions
and bioﬁlm can move more easily within the lungs. Bioﬁlm,
itself, acts as a nidus for inoculation in the lower respiratory
tract, with the potential for VAP [26, 31, 32]. VAP is associated with prolonged hospitalizations, increased length of
stay in an ICU, and increased costs.
To address these problems, a number of long established
and innovative modiﬁcations to respiratory care and
medical treatment practices have been developed to improve
artiﬁcial airways, limit airway contamination, decrease infection rate, reduce airway resistance, return ET tube patency, and improve outcomes of mechanically ventilated
patients. Currently, the institutional standard of care
commonly used to clear secretions from an ETT is blind
tracheal suctioning through a closed system [33, 34]. This
maneuver, however, has been found to be poorly eﬀective, as
the literature has shown blind suctioning to decrease lung
volume leading to hypoxia, trigger cardiac arrhythmias,
increase intracranial pressure, and detach aggregates of ETT
bioﬁlm into the lower respiratory tract [26, 33]. Several
researchers [33], also found a signiﬁcant degree of ETT
luminal obstruction in intubated patients despite optimal
humidiﬁcation and standard ETT suctioning.
To combat the collection of contaminated secretions
above the ETT cuﬀ, subglottic suctioning was established.
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Subglottic suctioning is a method that requires the use of a
modiﬁed ETT with subglottic suction capability. It is recommended for patients who require more than 72 hours of
mechanical ventilation [34, 35]. Subglottic suctioning has
been shown to cause tracheal mucosa damage, as well as,
tracheal injury immediately adjacent to the subglottic suction [22, 25, 35]. Suction dysfunction has raised concerns
about safety, as dysfunction has been attributed to obstruction of the subglottic suction port by suctioned tracheal
mucosa [26, 35].
In recent years, several researchers and companies have
focused their eﬀorts to develop novel medical devices
(e.g., Mucus Shaver, Obstruction Remover, Mucus Slurper,
and Rescue Cath), diﬀerent from suctioning, aimed speciﬁcally at cleaning the ETT lumen by removing secretions
attached to the ETT by physically scraping or wiping the
internal surface of the ET tube [12, 25, 33]. Acoustic reﬂectometry, high-resolution computed tomography [33],
intraluminal catheter, pressure oscillation analyses [36],
sound analysis [37], and resistive work of breathing are all
methods used to evaluate modiﬁed ETTs and ETT devices by
researchers. Although potential beneﬁts may exist, most
studies involved partial assessments of the ETT, which in
turn could potentially aﬀect the validity and eﬃcacy of the
method. In addition, large clinical trials and laboratory
studies have been limited in the testing of these medical
devices as they lack accurate measurements of ETT patency
and have not provided concrete evidence for wide use
[12, 33, 34, 38].
Our study aimed at overcoming the shortcomings of
previous trials by a more rigorous design and at developing a
standardized testing procedure to measure the impact of an
ETT-clearing device (ETT-CD) in returning the ETT to
luminal patency within controlled ex vivo conditions.
Mietto et al. [12] estimated that the average loss of
intraluminal ETT volume from partial occlusion due to
secretion accumulation was between 9 and 15%. Our results
estimated that nearly 25% of ET tubes at size 7.0 mm, 65% at
size 7.5 mm, and 74% at size 8.0 mm had a measurable
pressure drop equivalent to one size smaller. More apparent
was the decrease in pressure drops in ETT tubes sizes 7.5 mm
and 8.0 mm where 41% of 7.5 mm and 63% of 8.0 mm were
estimated to function at the same value as ETTs two sizes
smaller. We did not ﬁnd any underlying factors associated
with the increase in bioﬁlm secretions within the ETT lumen. We did, however, ﬁnd a positive correlation between
the volume extracted from the ETT lumen and pressure drop
observed in the multistation ventilator ﬁeld performance
testing simulator, independent of LOI.
Unlike Glass et al. [11], who predicted the longer the
time an ETT was in place, the greater the opportunity for
debris to accumulate, our ﬁndings closely matched those of
Wilson et al. [13], who illustrated the unpredictable nature of
ET tube obstruction and its independence of LOI. Consistent
with Wilson et al.’s ﬁndings [13], a patient intubated 3 hrs or
300 hrs could have either signiﬁcant increases in resistance
or measurements equivalent to those of size-matched
control tubes. The amount of bioﬁlm secretions within
the ETT lumen was not a time-related event [13]; hence,
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partial occlusion due to secretion accumulation cannot be
recklessly ignored.
Our results show that ex vivo ET tubes, before clearing,
had pronounced pressure drops (and therefore a higher
degree of resistance) of 32–158% from control tubes at the
7.5 mm and 8.0 mm luminal sizes. We tested the eﬃcacy,
safety, and feasibility of the ETT-CD in an ex vivo model,
which reduced luminal bioﬁlm secretions of ETTs to within
5–13% of the pressure drop observed in control tubes. Not
only was the ETT-CD found to be easy to use but it also was
eﬀective in removing secretions from the ETT lumens in the
7.5 mm and 8.0 mm tubes.
4.1. Limitations. Although the sample size (n � 40) was
adequate for statistical observations regarding device impact
and clinical associations, the small sample number of size
7.0 mm ETTs (n � 4) limits our ﬁndings for that diameter
ETT; nevertheless, consistent results were found for all of the
ETTs studied. Moreover, the study was not powered to
evaluate the eﬃcacy of the ETT-CD to respiratory care and
medical treatment practices, such as, standard suctioning.
The study was designed to evaluate the ETT-CD and its
ability to remove luminal bioﬁlm secretions and thereby
increase patency of the ETT. Larger studies are needed to
determine whether the use of the ETT-CD has any eﬀect on
VAP incidence, mortality, duration of MV, and ICU or
hospital stay. The three ETTsizes collected and tested against
the ETT-CD had internal diameters of 7.0, 7.5, and 8.0 mm
because these are the ETT sizes used for adults in our MICU/
SICU. Additional studies are needed to validate ETT-CD
functionality in smaller ETTs, as well as, comparative studies
against blind tracheal suctioning through a closed system,
the institutional standard of care.

5. Conclusion
Within hours following tracheal intubation, ETTs in MV
patients begin to accumulate luminal bioﬁlm secretions
causing narrowing or even occlusion of the ETT, as previously reported. The extent of the bioﬁlm accumulation and
occlusion in any one patient is unpredictable. The ETT-CD
was designed to clear the lumen of the ETT while the tube is
functioning as a conduit airway from the patient’s trachea to
the mechanical ventilator without the use of antimicrobials.
The newly designed multistation ventilator ﬁeld performance testing simulator allowed for a more representative
means to evaluate the impact of any clearing device in reducing airway resistance. Following the use of the ETT-CD,
the 7.5 mm and 8.0 mm ex vivo ETTs in the study were
signiﬁcantly improved over the ETTs before being cleared,
independent of occlusion location, tube size, or length of
tube.

Data Availability
The SPSS data used to support the ﬁndings of this study are
restricted by the West Virginia University Institutional
Review Board in order to protect patient privacy. Data are
available from the corresponding author, Christopher
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Waters, for researchers who meet the criteria for access to
conﬁdential data.

Disclosure
The contents of this manuscript were orally presented as a
poster by Christopher Waters at ASM 51st ICAAC for
September, 2011 in Chicago, IL, and CHEST 2012 for October, 2012 in Atlanta, GA. The content is solely the responsibility of the authors and does not necessarily represent
the oﬃcial views of the National Institutes of Health. The
funders had no role in study design, data collection and
analysis, decision to publish, or preparation of the
manuscript.

handle and trigger to deploy wiper, and (D) wiper, (D1)
wiper closer, and (D2) wiper deployed. Supplemental Figure 4: schematic representation of the endOclear endotracheal tube-clearing device. Positioning of the ECCD in the
ETT: (1) bullet-shaped tip of the ﬂexible central tube reached
Murphy’s eye of the ETT, (2) the disc-shaped wiper, set back
from the tip, and (3) activating handle of device deploys
wiper. The ECCD is pulled back out of the tube, extracting
bioﬁlm secretions clearing the ETT. Supplemental Figure 5:
comparison of the average percent (%) increase in pressure
drop of ETTs (before and after clearing) from control ET
tubes for each sized ETT, 7.0, 7.5, and 8.0 mm at ﬂow rates,
30, 60, and 90 L/min. (Supplementary Materials)
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Supplementary Materials
Supplemental Table 1: functionality of uncleared ETTs in
relation to ETT size. Supplemental Figure 1: schematic
representation of the multistation ventilator ﬁeld performance testing simulator. The simulator is organized into
four regions for quality control used in evaluating pressure
drop (before and after clearing) accompanied by a step-bystep schematic representing placement of extubated ETT
from 37°C “heated head” to PTS-2000. Supplemental Figure 2: measured pressure drop of each extubated patient
endotracheal tube; control, before the ETT was cleared (pre),
and after the ETT was cleared (post) evaluated at ﬂow rates
of (A) 30 L/min, (B) 60 L/min, and (C) 90 L/min. Supplemental Figure 3: exact representation of the endOclear
endotracheal tube-clearing device (ECCD). The endOclear
endotracheal tube-clearing device is composed of four
components: (A) depth stop, (B) red safety toggle, (C)
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